Evidence map›Paper›PMID 27889798›Full record

ArticleCancer immunology, immunotherapy : CII2017

Selective effect of cytokine-induced killer cells on survival of patients with early-stage melanoma.

Hong Li, Lan Huang, Linbo Liu, Ximei Wang, Zhen Zhang, Dongli Yue, Wei He, Kun Fu, Xueli Guo, Jianmin Huang and 9 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Hong LiBiotherapy Center, The First Affiliated Hospital, Zhengzhou University, Building #9, 1 Jianshe East Road, Zhengzhou, 450052, Henan, China.
Lan HuangBiotherapy Center, The First Affiliated Hospital, Zhengzhou University, Building #9, 1 Jianshe East Road, Zhengzhou, 450052, Henan, China.
Linbo LiuDepartment of Plastic Surgery, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, 450052, Henan, China.
Ximei WangDepartment of Plastic Surgery, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, 450052, Henan, China.
Zhen ZhangBiotherapy Center, The First Affiliated Hospital, Zhengzhou University, Building #9, 1 Jianshe East Road, Zhengzhou, 450052, Henan, China.
Dongli YueBiotherapy Center, The First Affiliated Hospital, Zhengzhou University, Building #9, 1 Jianshe East Road, Zhengzhou, 450052, Henan, China.
Wei HeDepartment of Oral and Maxillofacial Surgery, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, 450052, China.
Kun FuDepartment of Oral and Maxillofacial Surgery, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, 450052, China.
Xueli GuoDepartment of Vascular Surgery, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, 450052, Henan, China.
Jianmin HuangBiotherapy Center, The First Affiliated Hospital, Zhengzhou University, Building #9, 1 Jianshe East Road, Zhengzhou, 450052, Henan, China.
Xuan ZhaoBiotherapy Center, The First Affiliated Hospital, Zhengzhou University, Building #9, 1 Jianshe East Road, Zhengzhou, 450052, Henan, China.
Yu ZhuDepartment of Ophthalmology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, 450052, Henan, China.
Liping WangDepartment of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, 450052, China.
Wenjie DongDepartment of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, 450052, China.
Yan YanDepartment of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, 450052, China.
Li XuDepartment of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, 450052, China.
Ming GaoDepartment of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, 450052, China.
Shuangning YangBiotherapy Center, The First Affiliated Hospital, Zhengzhou University, Building #9, 1 Jianshe East Road, Zhengzhou, 450052, Henan, China.
Yi ZhangBiotherapy Center, The First Affiliated Hospital, Zhengzhou University, Building #9, 1 Jianshe East Road, Zhengzhou, 450052, Henan, China. yizhang@zzu.edu.cn.
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adoptive immunotherapy using cytokine-induced killer (CIK) cells has shown potential antitumor ability against several kinds of cancers, including melanoma. However, little is known about the achievable outcome of CIK cells in melanoma patients at different pathological stages. Here we recruited 55 patients treated with conventional therapy plus CIK cells as the CIK group, and 49 patients treated with conventional therapy alone as the control group. The pathological characteristics were comparable between two groups, with a follow-up period up to 40 months. Survival data and immune responses were evaluated after CIK cell treatment. In this study, CIK cells were successfully generated from peripheral blood of melanoma patients after in vitro culture for 14 days. The cultured CIK cells not only produced high levels of pro-inflammatory cytokines upon in vitro stimulation but also efficiently killed human melanoma cell lines. No serious side events were observed in all patients treated with CIK cells. Furthermore, infusions of CIK cells improved the quality of life in some patients, including advanced cases. More importantly, the CIK group exhibited better survival rates compared to the control group among early-stage melanoma patients, in consistent with the increased frequency of peripheral CD4

Indexed as

ApoptosisCell Line, TumorCytokine-Induced Killer CellsFemaleHumansImmunotherapy, AdoptiveK562 CellsMaleMelanomaMiddle AgedNeoplasm StagingRetrospective StudiesSurvival AnalysisClinical efficiencyCytokine-induced killer cellsImmunotherapyMelanomaSafety

Identifiers

PMID27889798
PMCPMC11028712
OpenAlexW2550266317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.